Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Tolerability of Soticlestat in Developmental Epileptic Encephalopathies (ENDYMION 1)
NCT03635073Phase 2Terminated
- Sponsor
- Takeda
- Start
- Jul 2018
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of soticlestat in developmental and epileptic encephalopathy (DEE), Dravet syndrome, Lennox-Gastaut syndrome (LGS) and 2 more, sponsored by Takeda. Primary endpoints: Treatment-emergent Adverse Event up to 84 months, Vineland Adaptive Behavior Scale at Week 338 and 7 more. Started Jul 2018; status: terminated.
02
Drugs
soticlestat
03
Conditions
developmental and epileptic encephalopathy (DEE)Dravet syndromeLennox-Gastaut syndrome (LGS)CDKL5 deficiency disorder (CDD)chromosome 15q11.2-q13.1 duplication syndrome (Dup15q)
Beyond the preview
Go deeper on NCT03635073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635073.